Valuation: CStone Pharmaceuticals

Market Cap 7.38B 1.1B 940M 880M 805M 1.51B 105B 1.53B 10.39B 4.05B 52.75B 4.12B 4.03B 174B P/E 2026 *
-346x
P/E 2027 * 6.89x
Enterprise Value 6.85B 1.02B 873M 817M 748M 1.4B 97.49B 1.42B 9.65B 3.76B 48.97B 3.83B 3.74B 162B EV / Sales 2026 *
14.3x
EV / Sales 2027 * 2.2x
Free-Float
80.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: CStone Pharmaceuticals

1 day-19.32%
1 week-2.03%
Current month-3.41%
1 month-3.41%
3 months-32.10%
6 months-15.16%
Current year-23.20%
1 month 0.69
Extreme 0.6858
0.7
Current year 0.59
Extreme 0.5945
1.01
1 year 0.59
Extreme 0.5945
1.01
3 years 0.11
Extreme 0.1139
1.01
5 years 0.11
Extreme 0.1139
1.78
10 years 0
Extreme 0.0001
2.6
Manager TitleAgeSince
Chief Executive Officer 62 2022-08-24
Director of Finance/CFO - 2023-01-17
Chief Operating Officer 46 2016-07-31
Director TitleAgeSince
Chairman 55 -
Director/Board Member 62 2022-08-24
Director/Board Member 63 2021-07-08
Change 5-day change 1-year change 3-year change Capi.($)
-19.32%-2.03% - - 1.1B
+0.90%+3.80%+41.49%-0.81% 83.28B
+8.86%+129.20%+435.14%+25.70% 57.94B
+0.68%+25.98%-21.64%-35.73% 57.77B
-1.46%+0.19%-2.06%+32.21% 51.75B
+1.74%+4.43%+12.37%+169.91% 49.35B
+1.13%+3.31%+55.61%-18.13% 32.03B
+0.46%+6.37%+50.29%+97.70% 25.91B
-2.15%+5.09%+0.25%+189.18% 22.74B
-0.30%+4.45%+58.29%+111.01% 16.87B
Average -0.94%+20.47%+69.97%+63.45% 44.18B
Weighted average by Cap. +1.54%+24.98%+80.46%+44.09%

Financials

2026 *2027 *
Net sales 479M 71.3M 61.08M 57.15M 52.31M 98.18M 6.82B 99.47M 675M 263M 3.43B 268M 262M 11.34B 1.71B 255M 218M 204M 187M 351M 24.39B 356M 2.41B 941M 12.25B 957M 936M 40.52B
Net income -243M -36.18M -30.99M -29M -26.54M -49.81M -3.46B -50.47M -343M -134M -1.74B -136M -133M -5.75B 687M 102M 87.6M 81.96M 75.03M 141M 9.78B 143M 968M 378M 4.92B 384M 376M 16.26B
Net Debt -528M -78.57M -67.31M -62.98M -57.65M -108M -7.52B -110M -744M -290M -3.78B -295M -289M -12.49B -3.6B -536M -459M -430M -393M -738M -51.28B -748M -5.08B -1.98B -25.76B -2.01B -1.97B -85.21B
Logo CStone Pharmaceuticals
CStone Pharmaceuticals is an investment holding company primarily engaged in research and development of therapies for oncology, autoimmune and inflammation, and other key disease areas. Through its subsidiaries, the Company is primarily engaged in the research and development of biopharmaceutical products, the sales of pharmaceutical products, as well as the provision of license of its intellectual property (IP) or commercialization license. The Company’s products primarily include targeted therapies, AYVAKIT (avapritinib), GAVRETO (pralsetinib) and CEJEMLY (sugemalimab). The Company is also engaged in the development and commercialization of immuno-oncology. The Company primarily conducts its businesses in the domestic market and overseas markets, such as Central and Eastern Europe and Switzerland.
Employees
136
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.617CNY
Average target price
12.33CNY
Spread / Average Target
+167.08%

Quarterly revenue - Rate of surprise